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ABSTRACT 
 
Background: There is an urgent need to limit the metabolic side-effects of glucocorticoid overexposure as these 
can lead to Cushing’s syndrome, associated with high morbidity. We have explored the potential for metformin 
to ameliorate such effects whilst sparing the anti-inflammatory benefits of glucocorticoids. 
Methods: In this double-blind, phase 2 proof-of-concept trial, 53 patients without known diabetes established 
on mid-to-high doses of glucocorticoids, administered as treatment for a chronic inflammatory disease, were 
randomised to receive 2550mg/day metformin (n=26) or an identical placebo (n=27) for 12 weeks. The primary 
endpoint was the change in visceral to truncal subcutaneous fat ratio assessed by computed tomography; 
secondary endpoints involved metabolic, bone, cardiovascular and inflammatory parameters. 
Findings: Nineteen patients on metformin and 21 on placebo completed the study. The groups received 
 
equivalent cumulative dose of glucocorticoids (1860mg (IQR 1060 to 2810) vs. 1770mg (IQR 1020-2356) 
 
prednisolone equivalent; p=0.76). There was no change in the visceral-to-subcutaneous fat ratio (0.11 (95%CI - 
 
0.02 to 0.24); p=0.09) between the treatment groups but metformin-treated patients lost truncal subcutaneous 
 
fat (-3835mm2 (95%CI -6781 to -888); p=0.01) compared to placebo. Improvements in markers of carbohydrate, 
lipid, liver and bone metabolism were observed on metformin. Additionally, metformin-treated patients had 
improved fibrinolysis, carotid intima-media thickness, inflammatory parameters and clinical markers of disease 
activity. The frequency of pneumonia (1 vs. 7 events; p=0.01), overall rate of moderate-to-severe infections (2 
vs. 11; p=0.001), and all-cause hospital admissions due to adverse events (1 vs. 9; p=0.001) were lower in the 
metformin group compared with placebo. Metformin-treated patients experienced more diarrhoea initially. 
 
Interpretation: Metformin administration improved the metabolic profile of glucocorticoid-treated patients 
 
with inflammatory disease, favourably modifying cardiovascular risk surrogates,  reducing  inflammation  and 
 
hospitalisation. 
 
Funding: Barts Charity, Merck Serono. ClinicalTrials.gov NCT01319994. 
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Research in context 
 
Evidence before this study 
 
Glucocorticoid excess, due to endogenous causes or to glucocorticoid treatment, can lead to Cushing’s syndrome, a 
phenotype associated with an increased morbidity and mortality. The higher morbidity risk lasts even after removal of 
glucocorticoid excess. 
 
Our team have previously shown that several metabolic changes associated with glucocorticoid overexposure 
correspond to metabolic steps regulated by 5’AMP-activated-protein-kinase (AMPK). AMPK is one of the mediators 
of metformin’s action: metformin was able to reverse the glucocorticoid effect on AMPK in vitro and to prevent 
glycaemic deterioration in non-diabetic patients when initiated simultaneously with glucocorticoid treatment. 
 
Metformin treatment was shown to be associated with metabolic benefits on weight, blood pressure, lipids, coagulation, 
inflammation, and endothelium in some, but not all, human studies. We wondered whether metformin administration 
for patients with glucocorticoid treatment might result in beneficial metabolic effects without adversely affecting their 
anti-inflammatory actions. 
 
Added value of this study 
 
This randomised, double-blind, placebo-controlled, phase 2 clinical trial evaluated patients established on 
glucocorticoid treatment, without diabetes, for the potential beneficial effects of metformin to diminish multisystem 
adverse effects of glucocorticoid treatment. Our data do not just show improvement in several surrogates of metabolic 
and cardiovascular risks for patients receiving metformin, but the intervention also appeared to reduce inflammation 
and number of infections and hospitalisation of this vulnerable patient cohort. The results are clinically relevant, and 
could be applied efficiently and economically to a large number of patients worldwide. 
 
Implications of all the available evidence 
 
Although glucocorticoids are the most common cause of medication-induced hyperglycaemia, and rising glycaemia 
has been reported as the number one concern when prescribing glucocorticoid treatment, there is no international 
consensus on the screening and management of glucocorticoid-induced hyperglycaemia. Based on experimental data, 
metformin’s mode of action may interact with the glucocorticoid pathway. We propose that metformin, irrespective of 
the diabetic status, could be a good agent to attenuate adverse effects of glucocorticoid treatment, reducing 
inflammation and cost, and improving patient outcomes. In view of limitations of lifestyle intervention for patients in 
need of glucocorticoid therapy, based on this study we recommend patients be considered for concomitant metformin 
treatment early and that larger studies are initiated to evaluate hard cardiovascular endpoints. 
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INTRODUCTION 
 
Glucocorticoid treatment is prescribed long-term in up to 3% of the adult population1,2. Chronic exposure to 
glucocorticoid excess can lead to distinctive truncal obesity, hypertension, hyperglycaemia, dyslipidaemia, 
hypercoagulability, fatty liver, osteoporosis, increased infections and other complications3. The developing 
phenotype, known as iatrogenic Cushing’s syndrome, is associated with increased morbidity and mortality, 
especially from cardiovascular causes and infections3,4
 
and the raised morbidity persists even after abrogation 
of glucocorticoid excess5,6. Separating the desired anti-inflammatory effects of glucocorticoids from their 
unwanted metabolic action has so far proved difficult. 
In patients with Cushing’s syndrome, the activity of one of the enzymatic mediators of metformin’s action, 
5’AMP-activated-protein-kinase (AMPK)7, was decreased in visceral adipose tissue8 while metformin reversed 
the glucocorticoid effect on AMPK in adipose and hypothalamic tissues in vitro9, and improved glucose levels 
in patients who were starting glucocorticoid treatment10. Metformin was also associated with a favourable 
immune response in several animal models of autoimmune diseases7. We hypothesised that metformin might 
alleviate a plethora of metabolic features of glucocorticoid overexposure without adversely affecting their anti- 
inflammatory benefits. Therefore, we designed a randomised, double-blind, placebo-controlled, phase 2 proof- 
of-concept trial of the addition of metformin therapy in patients with chronic inflammatory diseases already 
established on long-term glucocorticoid treatment. We wished to evaluate the potential of metformin to reverse 
multisystem glucocorticoid metabolic side-effects. There is clearly an urgent need for such a resolution but  no 
current solution. We aimed to improve the metabolic profile associated with glucocorticoid treatment and 
 
demonstrate that metabolically vulnerable patients with substantial cumulative glucocorticoid exposure 
significantly benefited from the administration of metformin. 
 
 
 
METHODS 
 
Participants 
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Eligible patients in this randomised, double-blind, placebo-controlled, phase 2 proof-of-concept trial were adults 
 
(≥18 and ≤75 years) with an inflammatory disease with ongoing ≥20mg/day prednisolone treatment for ≥4 weeks 
 
(or its cumulative dose-equivalent), remaining on ≥10mg/day prednisolone-equivalent for ≥12 subsequent 
 
weeks. Cumulative prednisolone equivalent was calculated using recognized conversion tables and both oral 
 
and parenteral glucocorticoids were taken into account. Minimum duration of continuous glucocorticoid 
exposure prior enrolment was 4 weeks, minimum cumulative dose: 560mg prednisolone equivalent. Key 
exclusion criteria were known pre-existing diabetes mellitus, prior therapy with metformin over the previous 6 
months,  ALT  and/or  AST  ≥2.5×upper  limit  of  normal,  or  serum  creatinine  ≥135µmol/L  (males)  and 
≥110µmol/L (females) (further details: Supplementary Methods). 
 
 
 
 
 
Study design, randomisation and masking 
 
 
After assessing 849 patients attending respiratory and rheumatology outpatient clinics regarding the presence of 
 
current  glucocorticoid  treatment  and  other  study-entry  criteria,  53  patients  were  randomised  to  receive 
 
metformin (n=26 subjects) or placebo (n=27) for 12 weeks (Figure 1). Participants were allocated to metformin 
 
or  placebo  treatments (in a 1:1 ratio)  according to a pre-specified,  computer-generated randomisation  table, 
 
  using blocks of four, stratified according to age (≤45 years or >45) and BMI (≤27kg/m2 or >27). Sequentially 
numbered containers with metformin or placebo tablets of identical appearance, size, weight, and taste were 
 
issued to the eligible patients directly by the Pharmacy. Participants, investigators and treating physicians were 
 
blinded to the treatment allocation. 
 
Identical metformin (850mg; Merck Serono) or placebo tablets (850mg; Delpharm Laboratories) were 
administered in escalating doses to reduce gastrointestinal adverse events, aiming for 3×850mg/day: 850mg/day 
for the first 5 days, 2×850mg/day for the next 5 days and full-dose subsequently. Study drug was administered 
 
for 12 weeks. The glucocorticoids were titrated by the treating specialists, independently of the study, based on 
 
patients’  clinical  needs, with  glucocorticoids  dose reduced as soon as  clinical condition  would  allow. Four 
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patients withdrew due to gastrointestinal intolerance of the minimum acceptable dose (2×850mg) in the 
metformin group. Two patients withdrew from the placebo group due to the development of overt diabetes 
mellitus, and one for the glucocorticoid dose falling outside of inclusion criteria. Three patients in each group 
discontinued due to inability to adhere to the appointment schedule. This left 19 subjects on metformin and 21 
on placebo for analysis (Figure 1). 
The study was approved by an independent Ethics Committee (South East Research Ethics Committee, 
REC09/H1102/82) and conducted according to the Declaration of Helsinki. All patients gave written informed 
consent. 
 
 
 
Assessments 
 
The primary outcome was the between-group change in the visceral-to-subcutaneous fat area ratio over 12 
 
  weeks, assessed by computed tomography (CT)11, as this parameter, a recognised surrogate for metabolic risk12, 
 
was found to be markedly raised in patients with Cushing’s syndrome compared to matched subjects with simple 
 
  obesity11, with the cortisol burden corresponding to a reduced AMPK activity in visceral fat8 being reversed by 
 
metformin in vitro9. Secondary outcomes involved changes in the following parameters: anthropometric 
measurements, insulin resistance and β-cell function by the homeostasis model assessment (HOMA2)13, fasting 
and post 75g sucrose challenge fibroblast growth factor 21 (FGF21), glucose, and tumour necrosis factor-alpha 
(TNFα), lipid profile, high sensitivity C-reactive protein (hsCRP), fibrin clot properties, β-C-terminal 
telopeptide (βCTX), procollagen type 1 N-terminal propeptide (P1NP), and osteocalcin concentrations, bone 
density by dual-energy X-ray absorptiometry (DEXA), and carotid intima-media thickness (IMT) by Doppler 
ultrasound.   Appetite   was  examined   using  visual  analogue  scales  (VAS)  and  the   ‘Three  factor  eating 
questionnaire’14. Physical activity was  assessed via VAS and  the  National  Audit  of  Cardiac  Rehabilitation 
 
Minimum Dataset Short Physical Activity Questionnaire15. Symptom severity/intrinsic disease activity were 
evaluated by relevant VAS, and safety and clinical impact by types and the occurrence of adverse events. 
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Imaging and carbohydrate challenge were performed at 0 and 12 weeks. Physical examination, VAS and fasting 
blood sampling were conducted at 4-week intervals. Details of the imaging and assay protocols are described in 
the Supplementary Methods. 
 
 
 
Statistical analysis 
 
 
Sample size calculation for the primary outcome was based on differences between patients with endogenous 
 
  Cushing’s syndrome and matched subjects with simple obesity11. Considering that the difference in visceral- 
 
to-subcutaneous adipose tissue area ratio was 0.845±0.525 (n=24) for patients with Cushing’s syndrome and 
 
0.28±0.17 (n=10) for obese controls, this results in a population mean difference of 0.57 with a standard 
 
deviation using pooled estimate of variance of 0.45. 90% power at 5% significance, the estimated sample sizes 
 
were 15 experimental subjects and 15 controls. Allowing for the short duration of treatment and heterogeneity 
 
of the study population with inflammation on exogenous glucocorticoids, the target was 20 patients 
 
completing the study in each arm. Our analysis followed the modified intention-to-treat principle in which 
 
individuals completing the study were analysed in the groups to which they were randomised (Supplementary 
 
Material). For continuous data, normality was assessed by the Shapiro-Wilk normality test and comparison of 
 
variances by the F-test; two-sample t-test for equal variances or Mann-Whitney tests were used for between- 
group analysis; paired t-test or Wilcoxon signed-rank test were conducted for within-group comparisons. 
Parametric data are reported as a mean ± standard deviation, non-parametric as a median and interquartile 
 
range (IQR). Group analysis was performed by repeated-measures two-way ANOVA. Multivariate regression 
 
model was used for adjustment for baseline variables as required. Mixed-effect regression was done for 
 
assessment of covariants at different time-points. Categorical data were examined by chi-square or Fisher’s 
 
exact tests in cases of few events. Pre-determined relevant correlations were computed by Pearson or 
 
Spearman rank-tests (correlation strength was defined by r-value: 0.3 to 0.69 (moderate), ≥0.7 (strong)). Given 
 
small group sizes, analysis reflects all available data without adjustment for missing data and the results were 
 
not adjusted for multiple testing. A p-value of <0.05 was considered statistically significant. 
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RESULTS 
 
Baseline characteristics 
 
 
  Patients in the two treatment groups, although heterogeneous, were well-balanced in terms of age, sex, BMI and 
 
  underlying diagnosis both at randomisation (Table 1) and from those completing the study (Table 2, Table 
 
  S1&S3-12). There were no statistically significant differences in glucocorticoid exposure prior and during the 
 
  study between the treatment groups (Table 1, Table S1). For patients completing the study (Table S1), the 
 
  duration of continuous glucocorticoid treatment at recruitment was 36 (IQR 10-156) vs. 36 (IQR 7.5-126) 
 
  months (metformin vs. placebo; p=0.67) and the cumulative exposure over the study period was 1860mg 
    
  prednisolone-equivalent (IQR 1060-2810) vs. 1770mg (IQR 1020-2356) (metformin vs. placebo; p=0.76), 
 
having received continuous glucocorticoid treatment. 
 
 
 
  There was no between-group difference for participants’ baseline physical activity (Table 1, Table S1), which 
 
  was very low. Although all participants received the same advice on benefits of healthy eating and physical  
 
  activity at the start, only the placebo-treated patients reported a mild increase in physical activity over the course 
 
  of the study (Figure S1). Metformin and placebo treated patients did not match at randomisation and throughout 
 
  the study for one aspect of feeding behaviour, the cognitive restraint of eating (Table 1, Table S6), where 
 
  placebo-treated patients scored significantly higher (suggestive they could more easily follow dietary 
 
  restrictions). We have included these lifestyle factors, which in theory could favour the placebo-treated arm, in 
 
  an adjusted model for our primary outcome. The treatment adherence was similar between patients taking 
metformin and the placebo, 88±3% vs. 88±2%, metformin vs. placebo, p=0.85. 
 
 
 
 
 
Main findings 
 
 
 
 
 
Effect of metformin on body composition 
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The primary outcome, visceral-to-subcutaneous ratio, did not change in metformin-treated patients (Table 2). 
 
The truncal subcutaneous fat area decreased in metformin-treated patients relative to placebo (Figure 2a, Table 
 
2) over 12 weeks, but not visceral adiposity (+2501±4891mm2 vs. +443±6810, metformin vs. placebo, p=0.28). 
 
Adjustment  for  baseline  variables  (difference  in  self-reported  exercise,  attitude  to  diet  and  cumulative 
 
glucocorticoid exposure, ethnicity, BMI and FGF21) in a multivariate regression model did not alter the above 
 
conclusions (Table S2). 
 
 
Changes in weight and waist circumference did not reach statistical significance (Table 2, Table S3). On physical 
 
examination, two (10%) metformin-treated vs. 11 (52%) placebo-treated patients were noted to have more 
 
pronounced characteristic facial adiposity associated with Cushing’s syndrome, a so-called ‘moon face’. 
(p=0.007). 
 
 
 
 
Effect of metformin on carbohydrate and lipid metabolism and the liver function 
 
 
Glucose and HbA1c decreased in metformin-treated subjects (Figure 2b, Table 2), reducing the number of 
patients with dysglycaemia (defined as fasting glucose ≥6.1mmol/L or any 2h post-challenge glucose ≥7.816). 
At baseline, 4 patients in each group had dysglycaemia, whilst at the end of the study none of the metformin- 
treated and 7 (33%) of the placebo-treated patients were dysglycaemic (p=0.009). Metformin prevented 
worsening of insulin resistance (HOMA2IR) (Figure 2c, Table 2) and improved β-cell function, estimated as the 
HOMA2%B/HOMA2IR disposition index (Figure 2d, Table 2), accounting for a compensatory increase in 
insulin secretion. The lipid profile (Figure 2e, Table 2, Table S4) and liver function tests (Figure 2f, Table S5) 
 
improved in metformin-treated subjects. Changes in AST/ALT (r=-0.47, p=0.02) and GGT (r=0.55, p=0.008) 
 
correlated with insulin resistance. Considering metabolic syndrome risk factors, the worse were the initial 
 
parameters, the greater were the improvements in waist circumference (r=-0.57, p=0.01), HOMA2IR (r=-0.54, 
 
p=0.02), glucose (r=-0.62, p=0.005), triglycerides (r=-0.63, p=0.004), LDL (r=-0.46, p=0.046) and HDL (r=- 
 
0.49, p=0.001) with metformin over the study period. Metformin had no effect on blood pressure. 
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Effect of metformin on appetite 
 
 
Hunger (Figure 2g, Table S6), sugar craving (Figure 2h) and disinhibition of eating (p=0.02) (Table S6) were 
 
reduced in metformin-treated subjects. Glucocorticoid treatment doses correlated positively to hunger (r=0.33, 
p=0.04) and sugar craving (r=0.40, p=0.02). The hunger scores, sugar craving and disinhibition correlated 
positively to fat body composition changes and insulin resistance (Supplementary Material). 
 
 
 
Effect of metformin on FGF21 and adiponectin 
 
Fasting FGF21 and adiponectin concentrations increased over 12 weeks in metformin-treated patients (Table 2). 
We identified an increase in FGF21 in response to sucrose challenge (76.2pg/mL (IQR 33.3-168.0) to 154.8 
(IQR 50.8-472.6), baseline to peak, n=50, p=0.003), but there was no between-group post-challenge difference 
(Table 2). FGF21 and adiponectin changes correlated significantly with nearly all favourable study outcomes 
(Supplementary Material). 
 
 
 
Effect of metformin on fibrinolysis and intima-media thickness 
 
 
Fibrin clot lysis time (Figure 3a, Table 2), an assay measuring fibrinolytic potential, was reduced in metformin- 
 
treated subjects while there was no significant effect on maximum absorbance, a parameter assessing clot density 
 
and fibre thickness (Table S7). Progression of IMT was attenuated in metformin-treated subjects (Table 2). The 
higher the entry IMT, the greater was any IMT reduction on metformin (r=-0.46, p=0.048). 
 
 
 
 
Effect of metformin on bone turnover and bone mass 
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The bone resorption marker βCTX decreased in metformin-treated patients (Figure 3e-f). P1NP, representing 
 
bone formation, and osteocalcin, reflecting both formation and resorption, did not change significantly (Table 
 
S8-S12). The treatment groups were matched for bisphosphonate treatment and vitamin D concentrations 
 
(Table S12). Bone mineral density (BMD) at the hip (Figure 3d, Table 2&S8-S9) increased in metformin- 
 
treated patients. This increase persisted after adjustment for changes in hip circumference and weight in a 
 
multivariate regression model (p=0.02). Three (19%) metformin-treated subjects reduced their hip BMD 
 
compared to 14 (67%) patients on placebo (p=0.007). No changes were identified at the spine (Table S8-S9). 
 
 
 
Effect of metformin on inflammation and clinical safety outcomes 
 
 
hsCRP decreased in metformin-treated subjects compared to placebo (Figure 3b, Table 2). Total white cell- 
 
count and neutrophil count reduced from baseline within the metformin group but the between-group 
 
difference did not reach statistical significance (Table 2). Carbohydrate-challenged TNFα levels increased 
 
significantly compared to pre-treatment in the placebo cohort (p=0.04), but not in the metformin group (Figure 
 
S2). In a mixed effect regression model incorporating glucocorticoid dose change during the study, white cell- 
 
  count decreased with decreasing glucocorticoid dose by 0.07109/L/mg prednisolone-equivalent decrease 
 
(p<0.001), with no statistically significant difference between metformin and placebo. Neutrophils decreased 
 
  with decreasing glucocorticoid dose by 0.06109/L/mg prednisolone-equivalent decrease (p=0.003) with no 
 
statistically significant difference between metformin and placebo (difference 0.49; p=0.60). hsCRP did not 
 
change with decreasing glucocorticoid dose (0.00006 increase per unit decrease in glucocorticoid dose; 
 
p=0.69) and there was a statistically significant difference between metformin and placebo (difference -0.1; 
 
p=0.03). 
 
Metformin-treated patients with respiratory conditions reported reduced dyspnoea (Figure 3c). Patients with 
rheumatic diseases taking metformin improved their global disease activity score (Table 2). There were more 
episodes of pneumonia, more severe infections and more respiratory and overall serious adverse events in the 
placebo arm (Table 3). Diarrhoea occurred more frequently in metformin-treated subjects (Table 3). 
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DISCUSSION 
 
In this study, metformin administration showed superiority to placebo in improving the metabolic profile and 
 
clinical outcomes in patients without known diabetes established on systemic glucocorticoid treatment for a 
chronic inflammatory disease. 
While no change was observed for the visceral-to-subcutaneous fat ratio (primary outcome) or the visceral fat 
 
mass during the 3-months study period, a modest reduction in truncal subcutaneous fat was seen in the 
 
metformin-treated patients. Metformin also appeared to prevent progression of facial adiposity. Truncal 
subcutaneous fat is known to expand in hypercortisolaemia17, alongside visceral fat11,17, and higher truncal 
subcutaneous fat contributes to the adverse cardiometabolic risk profile associated with central adiposity18. 
The visceral to subcutaneous ratio has been associated with cardiometabolic risk above and beyond body mass 
 
index and visceral adiposity in the Framingham Heart Study12. Metformin has been shown to qualitatively 
improve visceral fat irrespective of fat mass19 and to reduce abdominal subcutaneous fat in overweight patients 
with type 2 diabetes (T2DM)20, a cohort with the best cardiovascular outcome in the United Kingdom 
Prospective Diabetes Study7,21. Whilst glucocorticoid effects on adipose functionality are insufficiently known, 
our data suggest a multisystem metabolic advantage with glucocorticoid-metformin co-administration. The 
  AMPK-pathway may represent one of the mediators of glucocorticoid-metformin interaction8,9. Metformin 
 
  may interact with glucocorticoid metabolism via 11β-hydroxysteroid dehydrogenase-122, although this may 
 
not play a role in patients with supraphysiological doses of synthetic glucocorticoid treatment. 
 
Insulin resistance, β-cell function and glucose levels were improved in metformin-treated subjects compared to 
 
placebo which is clinically relevant, given the cohort’s propensity to diabetes. These findings together with 
improved liver function are in keeping with the reduced conversion from pre-diabetes to T2DM and improved 
liver function in metformin-treated subjects in the Diabetes Prevention Program23,24. Glucocorticoids increase 
glucose levels both at non-diabetic as well as diabetic glucose ranges25. Metformin’s ability to antagonise this 
glucose rise is important, as cardiovascular events increase linearly with rising glucose even in the non-diabetic 
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glucose range26. Moreover, increasing glucose often associates with poor outcomes16 and metformin has been 
shown to improve clinical outcomes where glucose parameters decreased in non-diabetic patients7,21. 
Glucocorticoid therapy, which can paradoxically induce a pro-inflammatory phenotype overlapping with the 
metabolic syndrome, is associated with increased cardiovascular morbidity and mortality5,6. The more florid the 
initial metabolic disturbances in our patients, the greater the detected benefits of metformin. Our finding of 19% 
lower LDL in statin-naïve metformin-treated patients, in line with reports from pre-diabetic cohorts7, may 
represent a considerable clinical benefit. Every 1% reduction in LDL by statins was associated with up to 2.5% 
lower cardiovascular events in inflammatory disease where glucocorticoid-related lipid side-effects can be 
confounded by their anti-inflammatory action27. 
Appetite stimulation by glucocorticoids represents a major drive for obesity28. Here we show that metformin, a 
 
drug with anorectic effects7, was associated with suppressed appetite and sugar craving, promoting abdominal 
fat loss, even when co-administered with glucocorticoids. Supporting this, glucocorticoids increased appetite in 
rodents, recruiting AMPK, an effect mitigated by metformin in vitro9. 
Fructose overconsumption, associated with adverse metabolic effects and altered glucocorticoid signalling, 
could contribute to a Cushingoid phenotype29. FGF21, a biomarker of fructose metabolism and crucial in 
cardiometabolic protection, robustly and rapidly increases in response to fructose ingestion differentially from 
glucose29. Here we identified a rise in FGF21 after a sucrose challenge in all groups. Metformin prevented a 
drop in fasting FGF21 and increased adiponectin, with the changes correlating favourably with nearly all study 
outcomes. We hypothesise that metformin may reduce glucocorticoid-related metabolic dysfunction and 
systemic inflammation by enhancing the FGF21-adiponectin axis. 
Both poorly-treated inflammatory disease and glucocorticoid overexposure represent prothrombotic phenotypes, 
associated with impaired fibrinolysis and an accelerated atherosclerosis6,30. Prolonged fibrin clot lysis time is an 
independent predictor of cardiovascular mortality31; here we demonstrate enhanced fibrinolysis in metformin- 
 
treated patients. Metformin is believed to improve the hypofibrinolytic environment in T2DM, with this effect 
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proposed to contribute substantially to the reduced cardiovascular risk attributed to metformin in the United 
Kingdom Prospective Diabetes Study32. Our data mark potentially a major advantage for metformin in reducing 
thrombosis risk in glucocorticoid-treated patients. 
IMT is a widely accepted surrogate marker for a generalised clinical/subclinical atherosclerosis, correlating to 
the risk of development of atherosclerotic plaques and coronary events in the majority of trials33. Metformin 
treatment was associated with a reduced progression of IMT in this heterogeneous cohort, similar to the benefits 
 
identified in subjects  with the  metabolic syndrome of  T1DM & T2DM7,33,34 unlike in non-diabetic  patients 
 
established on statins for coronary disease where metformin did not reduce LDL35. A longer treatment study is 
 
warranted to probe into the mechanistic pathways that are responsible for the protective effects of metformin in 
 
patients on glucocorticoids. 
 
 
There was a reduction in inflammation (hsCRP) and improvement in patient-oriented clinical markers of disease 
 
activity in metformin-treated patients who also appeared to have a better infection profile. This is clinically 
 
relevant, given the participants’ severe immunosuppression. There were fewer episodes of pneumonia, milder 
infective events, no severe asthma exacerbation and less overall serious adverse events in metformin-treated 
patients. Although warranting an exploration in a larger study, these results point to up to 30% absolute risk 
reduction of moderate-to-severe infections or all-cause hospital admissions, which corresponds to treating 3 
patients with metformin to prevent one case. The beneficial effect of lower glucose levels on immunomodulation 
is likely. Nonetheless, there is growing evidence that metformin has discrete anti-inflammatory properties 
beyond this36. In experimental models, metformin prevented lung infections independently of glycaemia and 
reduced the inflammation of chronic asthma, uveitis and rheumatoid arthritis7,37,38. Metformin appeared to be 
superior to other glucose-lowering agents at reducing infections in T2DM38,39 and compared to placebo in 
PCOS40, independently of glycaemia. Moreover, others linked a greater burden of adverse events with a higher 
disease activity and reduced remissions41. As an acute treatment for chronic obstructive pulmonary disease 
exacerbations, metformin did not benefit non-diabetic individuals in a very short trial37, while in the chronic 
setting prescribing metformin in T2DM was associated with lower hospitalisation in patients with asthma or 
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chronic  obstructive  pulmonary  disease37.  Glucocorticoid  effects  on  the  immune  system are  complex, and 
   
  metformin’s interactions would deserve further exploration with immune profiling in a dedicated study42. 
 
Glucocorticoids are renowned for adverse bone effects6. In our metformin-treated patients there was a modest 
 
reduction in the bone resorption marker βCTX, with the overall bone turnover consistent with a bone mass 
 
increase, and a subtle bone mass increase was identified at the hip. This effect appeared to persist irrespective 
 
of the body composition assessed, vitamin D levels or bisphosphonate treatment, warranting further studies with 
 
greater patient numbers and using other assessment modalities to characterise the effect of confounding factors 
 
  in more detail, and to explore the clinical significance of these signal findings. Metformin prevented 
 
  glucocorticoid-induced bone loss in the femur of an animal model, differentially to the mode of action of 
 
alendronate43. Advantageous effects of metformin on fracture risk or bone mass were noted in subjects with 
T2DM44 and in PCOS40, possibly by modulating metabolic-immune interplay7. 
Glucocorticoid-related metabolic dysfunction offsets the drug’s profound anti-inflammatory benefits, 
contributing to the lasting increased morbidity associated with inflammatory diseases5,6. Metformin is effective 
in treating the endothelial dysfunction and the metabolic syndrome of PCOS7,45 and preventing glycaemic 
deterioration when initiated simulataneously with glucocorticoids in non-diabetic individuals10. Here we show 
wider  metabolic  and  clinical  benefits  in  subjects  already  established  on  glucocorticoid  treatment. While 
 
  metformin has shown favourable effects in different insulin resistant pathological states, no other studies have 
 
  been conducted to explore the role of this agent on vascular, thrombotic, inflammatory and bone markers 
 
following glucocorticoid treatment. The morbidity of the underlying disease and the glucocorticoid-driven 
increased appetite often limit intervention by lifestyle change. We suggest that metformin used in 
glucocorticoid-treated patients without diabetes may have the potential for improving treatment-related 
complications and cardiovascular prognosis. 
 
 
  Many patients on glucocorticoid tretament develop diabetes. Our recent study, for example, showed worsening 
 
  metabolic parameters (basal and 2h AUC glucose and cholesterol) in glucocortioid-treated patients (previously 
   
  not on glucocorticoids) on placebo compared to metformin treatment10. Our current study population on chronic 
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  glucococortcoid treatment, who did not have overt diabetes at study entry might, therefore, be somewhat less 
 
  predisposed to diabetes. We did not expect in our placebo group that metabolic parameters would worsen during 
 
  the 12-week study period, especially in face of reducing glucocorticoid doses over the 12-weeks (Table 1). 
 
 
  Indeed, only a few parameters showed modest worsening in the placebo group (Table 1 and Supplementary 
 
  Material). However, our data showed significant improvement in various parameters in the metformin-treated 
 
  group. These results raise the intriguing possibility to treat chronic inflammatory disease patients with metformin 
  even without concomitant glucocorticoid medication. 
 
 
 
 
Strength and weaknesses 
 
The strength of our study is its randomised, double-blind design in largely well-balanced treatment cohorts. 
Selected patients typify subjects with chronic active inflammation at a high risk for metabolic complications of 
iatrogenic Cushing’s syndrome not offered metformin in real-life practice. Our results are clinically pertinent 
and the cohort heterogeneity adds to the data generalizability. Metformin is available worldwide and could 
improve metabolic status of large number of patients; according to a recent study 3% of the overall general 
population, with even higher percentages in the older population (7% of 60-79 and 10% of over 80 years old 
subjects)2. 
Our study has several limitations, the main ones being the small sample size, heterogeneity of patients and the 
relatively short treatment duration. The initial sample size calculation was derived from records on patients with 
endogenous Cushing’s syndrome11, although data in patients with rheumatoid arthritis and other conditions 
 
supported our calculations46-48.  While various biases may affect parameters at different time points impacting 
 
  on the final conclusions, the direction of changes favouring metformin in the assessments appears consistent. 
 
  Given the small sample size, we report unadjusted findings; selection bias due our drop-out patients cannot be 
 
  fully excluded, although the remaining groups remained well-balanced and the drop-out rate was similar in both 
 
groups. The cohort size, heterogeneity and treatment duration limit the scope for exploring disease-specific and 
 
long-term clinical outcomes of interest. Given the sample size and relatively large number of secondary 
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outcomes, cautious interpretation is warranted; nevertheless, our data are concordant and contributory to the 
growing evidence of metformin’s benefits involving robust numbers of patients, especially those at diabetes 
risk. A larger study may help to both identify an optimal cohort of patients who would benefit most from this 
intervention and explore the subsequent clinical benefits suggested by this trial. 
 
 
 
In summary: We have carried out a randomised, double-blind, placebo-controlled, phase 2 proof-of-concept 
 
trial exploring the potential of metformin to improve the metabolic profile of established glucocorticoid 
treatment in patients without known diabetes burdened with chronic active inflammation. We have shown that 
metformin-treated patients showed a significant improvement in several prognostic parameters and clinical 
 
outcomes.  Compared  to  placebo,  metformin-treated  participants  had  reduced  appetite,  truncal  and  facial 
 
subcutaneous fat and insulin resistance, improved β-cell function, glycaemia, lipid profile, liver function, 
fibrinolysis, subclinical  atherosclerosis, bone  metabolism,  infection  risk,  inflammation, disease activity and 
symptom severity, as well as fewer hospital admissions. These results may indicate the possibilty of a major 
improvement in patient care and justify further research into the concomitant use of metformin in patients on 
glucocorticoid treatment. 
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Table 1: Baseline characteristics 
 
Reported as a mean ± standard deviation or as median (IQR: interquartile range) or as number (% out of randomized patients) 
 
 Metformin Placebo P- 
value 
Allocated number of patients 26 27 0.99 
Age 47±15 45 ±15 0.63 
Sex – female (%) 14 (54%) 15 (56%) 0.99 
Ethnicity Mixed Mixed 0.31 
- White 12 (46%) 17 (63%)  
- South Asian 6 (23%) 5 (18%)  
- Black/African American 5 (19%) 5 (18%)  
- Other (oriental; mixed White/South Asian) 3 (12%) 0  
BMI (kg/m2) 27.3 (IQR 23.3 to 36.1) 28.5 (IQR 24.7 to 35.8) 0.64 
Current smoker 6 (23%) 2 (7%) 0.14 
Smoking pack history 0 (IQR 0 to 6.3) 0 (IQR 0 to 5.0) 0.94 
Main indication for GC treatment Mixed Mixed 0.21 
- Asthma 7 (27%) 9 (33%)  
- Vasculitis (GCA/PNA/Wegener’s, non-specified) 7 (27%) 3 (11%)  
- Sarcoidosis 5 (19%) 1 (4%)  
- SLE 4 (15%) 5 (19%)  
- RA 1(4%) 2 (7%)  
- Interstitial lung disease (other than connective tissue disease-related) 1 (4%) 2 (7%)  
- Other (mixed connective tissue disease; isolated uveitis/scleritis/retinitis) 1 (4%) 1 (4%)  
- Myositis (other than SLE-related) 0 4 (15%)  
Duration of continuous systemic glucocorticoid treatment by the study entry (months) 24 (IQR 6 to 129) 36 (IQR 5 to 120) 0.98 
Estimated cumulative dose of glucocorticoids by the study entry (equivalent mg of prednisolone) 16 643 (IQR 2643 to 103275) 20 860 (IQR 8360 to 64400) 0.92 
Cumulative dose of glucocorticoid last 3 months prior to the study entry (equivalent mg prednisolone) 1845 (IQR 1273 to 2700) 2010 (IQR 1295 to 2930) 0.45 
Cumulative dose of glucocorticoids during the study (equivalent mg of prednisolone) 1782 ± 1092 1718 ± 805 0.82 
Prednisolone equivalent dose (mg) at the initial study visit 23 (IQR 12 to 40) 25 (IQR 12 to 40) 0.83 
Prednisolone-equivalent dose (mg) at 4 weeks 20 (IQR 10 to 28) 20 (IQR 10 to 29) 0.98 
Prednisolone-equivalent dose (mg) at 8 weeks 20 (IQR 10 to 30) 18 (10 to 22) 0.53 
Prednisolone-equivalent dose (mg) at 12 weeks 13 (IQR 10-25) 15 (IQR 10-25) 0.62 
Waist circumference (cm) 96.9 ± 17.3 100.2 ± 19.4 0.52 
Hip circumference (cm) 106.5 ± 16.1 108.9 ± 14.2 0.48 
Systolic BP (mm Hg) 121 ± 16 129 ± 20 0.14 
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 Metformin Placebo P- 
value 
Diastolic BP (mm Hg) 79 ± 12 83 ± 12 0.26 
Visceral abdominal fat (mm2) 22646 (IQR 16378 to 30746) 25984 (IQR 17211 to 35355) 0.36 
Subcutaneous abdominal fat (mm2) 48715 (IQR 36614 to 65124) 48485 (IQR 33278 to 62939) 0.98 
Visceral-to-subcutaneous fat ratio 0.44 (IQR 0.33 to 0.67) 0.58 (IQR 0.34 to 0.84) 0.49 
Fasting glucose (mmol/L) 4.7 (IQR 4.5 to 5.7) 4.9 (IQR 4.5 to 5.8) 0.38 
AUC glucose (mmol/L*min) post 75g sucrose challenge 826 (IQR 643 to 1054) 806 (IQR 717 to 1179) 0.87 
HbA1c (mmol/mol) 40 ± 6 39 ± 7 0.69 
HOMA2IR 4.7 (IQR 2.2 to 5.5) 4.1 (IQR 2.8 to 5.4) 0.97 
HOMA2%B 282.8 ± 132.9 254.9 ± 124.6 0.43 
HOMA2%B/HOMA2IR 68.3 ± 21.0 63.8 ± 24.8 0.48 
Total cholesterol (mmol/L) 5.6 (IQR 4.7 to 6.4) 5.4 (IQR 4.7 to 6.2) 0.66 
LDL (mmol/L) 2.8 (IQR 2.3 to 3.4) 2.9 (IQR 2.5 to 3.4) 0.71 
HDL (mmol/L) 1.86 ± 0.52 1.81 ± 0.46 0.67 
Triglycerides (mmol/L) 1.5 (IQR 1.0 to 2.3) 1.3 (IQR 1.1 to 1.8) 0.29 
ALT(U/L) 17 (IQR 14 to 25) 19 (IQR 14 to 26) 0.53 
ALP(U/L) 62 ±15 59 ±19 0.55 
FGF21 (pg/mL) 56.5 (IQR 27.3 to 156.3) 96.0 (IQR 41.5 to 256.8) 0.25 
Adiponectin (ng/mL) 22.0 (IQR 11.6 to 44.9) 21.8 (IQR 8.6 to 41.5) 0.60 
hsCRP (mg/L) 0.033 (IQR 0.009 to 0.049) 0.025 (IQR 0.010 to 0.050) 0.96 
Haemoglobin 13.2 ± 0.3 13.1 ± 0.3 0.89 
White cell count 10.2 ± 0.7 8.7 ± 0.8 0.18 
Neutrophils 7.4 (IQR 5.2 to 8.7) 5.8 (IQR 3.5 to 8.5) 0.15 
Lymphocytes 1.7 (IQR 1.2 to 2.8) 1.3 (IQR 0.8 to 2) 0.08 
Monocytes 0.6 ± 0.1 0.6 ± 0.1 0.91 
Eosinophils 0.1 (IQR 0.1 to 0.2) 0.1 (IQR 0 to 0.2) 0.23 
Basophils 0 (IQR 0 to 0) 0 (IQR 0 to 0.03) 0.40 
Platelets 254 (IQR 203 to 327) 233 (IQR 185 to 280) 0.46 
Intima-media thickness (mm) 0.50 (IQR 0.46 to 0.55) 0.51 (IQR 0.46 to 0.56) 0.77 
Lysis time (s) 354 (IQR 276 to 426) 366 (IQR 297 to 444) 0.53 
Lysis area (AU) 92.0 (IQR 60.7 to 126.7) 120.7 (IQR 72.9 to 218.5) 0.15 
Total hip BMD (g/cm2) 0.965 ± 0.145 0.988 ± 0.195 0.63 
Spine BMD (g/cm2) 0.981 ± 0.150 0.997 ± 0.168 0.73 
Vitamin D (nmol/L) 45.5.0 (IQR 29.0 to 58.3) 32.0 (IQR 25.0 to 71.5) 0.62 
βCTX (µg/L) 0.21 (IQR 0.17 to 0.33) 0.17 (IQR 0.08 to 0.31) 0.35 
P1NP (µg/L) 22.3 (IQR 13.9 to 34.7) 20.5 (IQR 12.9 to 39.1) 0.79 
Osteocalcin (µg/L) 9.3 (IQR 6.7 to 16.3) 9.6 (IQR 5.2 to 14.6) 0.64 
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 Metformin Placebo P- 
value 
Physical activity on the day of assessment (virtual scale 0-10. 10 is the highest) 2 (IQR 1 to 3.3) 2 (IQR 1 to 3) 0.20 
Reported frequency of at least 15min. of strenuous physical activity in 7 days (National Audit of 
Cardiac Rehabilitation (NACR) Minimum Dataset Short Physical Activity questionnaire) 
0 (IQR 0 to 0) 0 (IQR 0 to 0) 0.28 
Reported frequency of at least 15min of moderate physical activity in 7days (NACR questionnaire) 0 (IQR 0 to 0.5) 0 (IQR 0 to 2) 0.84 
Reported frequency of at least 15min of minimal effort physical activity in 7 days (NACR 
questionnaire) 
3.5 (IQR 0 to 7) 3 (IQR 2 to 7) 0.95 
Cognitive restraint of eating ^ 6 ± 4 9 ± 4 0.007 
Disinhibition of eating ^ 5 (IQR 3 to 10) 5 (IQR 2 to 8) 0.77 
Hunger^ 4 (IQR 2 to 9) 4. (IQR 2 to 8) 0.99 
Medications 
Prednisolone 25 (96%) 27 (100%) 0.49 
Methylprednisolone 0 1 (4%) 0.99 
Beclomethasone 1 (4%) 1 (4%) 0.99 
Fluticasone 4 (15%) 5 (19%) 0.99 
Dexamethasone 2 (8%) 0 0.22 
Clobetasone 1 (4%) 0 0.99 
Methotrexate 2 (8%) 3 (11%) 0.99 
Hydroxychloroquine 2 (8%) 4 (15%) 0.67 
Azathioprine 1 (4%) 1 (4%) 0.99 
Mycophenolate 1 (4%) 4 (15%) 0.35 
Sulphasalazine 1 (4%) 0 0.49 
Ustekinumab 0 1 (4%) 0.99 
Tocilizumab 0 1 (4%) 0.99 
Omaluzimab 1 (4%) 1 (4%) 0.99 
Cyclophosphamide 0 2 (7%) 0.49 
Ciclosporin 1 (4%) 1 (4%) 0.99 
Bronchodilators 11 (42%) 11 (41%) 0.99 
Bisphosphonates 12 (46%) 9 (33%) 0.41 
HRT/OCP 3 (12%) 0 0.11 
TB treatment 2 (8%) 1 (4%) 0.61 
Warfarin/LMWH 1 (4%) 2 (7%) 0.99 
Aspirin/clopidogrel 3 (12%) 5 (19%) 0.70 
Statins 4 (15%) 1 (4%) 0.19 
Antihypertensives 12 (46%) 11 (41%) 0.79 
Beta-blockers 3 (12%) 1 (4%) 0.61 
ACE-inhibitors/Sartans 9 (35%) 8 (30%) 0.77 
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MF, metformin; PL, placebo; BMI, body mass index; GC, glucocorticoid(s); GCA, giant cell arteritis; PNA, polyarteritis nodosa; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; LDL, low- 
density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; ALT, alanine aminotransferase; ALP, alkaline phosphatase; FGF21, fibroblast growth factor 21; ßCTX, ß-C-terminal telopeptide; 
P1NP, procollagen type 1 N-terminal propeptide; HRT, hormone replacement therapy; OCT, oral contraceptive therapy; LMWH, low molecular weight heparin; BMD, bone mineral density; AU, arbitrary 
units; ^Components of the Three factor eating questionnaire 
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Table 2. Outcome data 
Expressed as mean ± standard deviation or median and interquartile range (IQR) 
Metformin (MF) Placebo (PL) Difference between groups (P-value) 
 
Visceral-to-subcutaneous fat area (ratio) 
Baseline (MF n=19; PL n=21) 0.45 (IQR 0.32 to 0.77) 0.60 (IQR 0.36 to 0.89) 0.34 
At 12 weeks 0.56 (IQR 0.33 to 0.79) 0.59 (IQR 0.37 to 0.81) 0.92 
Change over 12 weeks 0.08 ± 0.19 -0.03 ± 0.22 0.09 
Difference within groups (P-value) 0.11 0.57 
 
Truncal subcutaneous fat area (mm2) 
   
Baseline (MF n=19; PL n=21) 48640 (IQR 33786 to 73959) 41753 (IQR 32760 to 58873) 0.70 
At 12 weeks 42643 (IQR 30519 to 72160) 45214 (IQR 34394 to 57371) 0.61 
Change over 12 weeks -2035 ± 4283 1799 ± 4859 0.01 
Difference within groups (P-value) 0.053 0.12 
 
 
Weight (kg) 
Baseline (MF n=19, PL n=21) 75(IQR 59.4 to 99) 79 (IQR 68 to 97) 0.56 
At 12 weeks 71 (IQR 58 to 103) 80 (IQR 69 to 99) 0.42 
Change over 12 weeks -1.1±0.8 0.5±0.5 0.09 
Difference within groups (p-value) 0.11 0.47  
Fasting glucose (mmol/L) 
Baseline (MF n=19; PL n=21) 5.0 (IQR 4.5 to 5.9) 4.9 (IQR 4.5 to 5.4) 0.82 
At 12 weeks 4.3 (IQR 4.1 to 4.6) 5.0 (IQR 4.4 to 5.6) 0.03 
Change over 12 weeks -0.5 (IQR -0.8 to -0.3) 0 (IQR -0.4 to 0.3) 0.005 
Difference within groups (P-value) 0.001 0.89 
 
AUC glucose (mmol/L*min) post 75g sucrose challenge 
Baseline (MF n=19; PL n=20) 837 (IQR 636 to 1140) 806 (IQR 712 to 1077) 0.80 
At 12 weeks 711 (IQR 552 to 816) 821 (IQR 749 to 1097) 0.01 
Change over 12 weeks -121.5 (IQR -306 to -24) 30.8 (IQR -60.4 to 108.4) 0.002 
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Difference within groups (P-value) 0.003 0.23 
 
HOMA2IR (Mass Units) 
Baseline (MF n=19; PL n=21) 4.63 (IQR 2.09 to 4.88) 3.82 (IQR 2.48 to 4.99) 0.95 
At 12 weeks 4.53 ± 2.1 6.20 ± 2.6 0.03 
Change over 12 weeks 0.22 ± 3.3 2.35 ± 3.2 0.04 
Difference within groups (P-value) 0.61 0.003 
 
Disposition index (HOMA2%B/HOMA2IR) 
Baseline (MF n=19; PL n=21) 66.5 ± 21.3 69.5 ± 23.2 0.68 
At 12 weeks 83.7 ± 21.9 63.2 ± 25.5 0.01 
Change over 12 weeks 17.1 ± 22.6 -6.3 ± 20.6 0.001 
Difference within groups (P-value) 0.004 0.18 
 
LDL cholesterol (mmol/L) 
Baseline (MF n=19, PL n=20) 2.6 (IQR 2.3 to 3.3) 2.9 (IQR 2.6 to 3.3) 0.33 
At 12 weeks 2.3 (IQR 1.9 to 2.7) 3.0 (IQR 2.4 to 3.8) 0.01 
Change over 12 weeks -0.4 (IQR -0.9 to 0.3) 0.2 (IQR -0.4 to 0.5) 0.08 
Difference within groups (P-value) 0.04 0.68 
 
Cholesterol:HDL ratio (Atherogenic index) change over 12 weeks (MF n=19; PL n=21) -0.26 ± 0.85 0.27 ± 0.71 0.04 
hsCRP (mg/L) 
Baseline (MF n=19, PL n=21) 0.031 ± 0.025 0.033 ± 0.024 0.86 
At 12 weeks 0.016 (IQR 0.006 to 0.029) 0.036 (IQR 0.021 to 0.050) 0.02 
Change over 12 weeks -0.010 ± 0.025 0.003 ± 0.026 0.09 
Difference within groups (P-value) 0.08 0.5731 
 
% change over 12 weeks -40.9 (IQR -82.9 to 45.4) 8.5 (IQR -30.3 to 128.6) 0.09 
AUC of 4 visits over 12 weeks 0.08±0.01 0.12±0.02 0.02 
White cell-count (109/L) 
   
Baseline (MF n=19 , PL n=19) 9.9 ± 0.9 8.9 ± 0.9 0.40 
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At 12 weeks 8.4 (IQR 6.6 to 10.3) 7.4 (IQR 5.9 to 10.9) 0.95 
Change over 12 weeks -1.0 (IQR -2.4 to -0.1) -0.6 (IQR -2.0 to 0.8) 0.25 
Difference within groups (P-value) 0.01 0.15 
 
Neutrophils 
   
Baseline (MF n=16; PL=17) 7.4 (IQR 4.5 to 9.6) 5.8 (IQR 3.8 to 8.1) 0.33 
At 12 weeks 4.6 (IQR 4 to 6.4) 4.2 (IQR 3.4 to 8.3) 0.69 
Change over 12 weeks -2.1 ± 0.6 -0.7 ± 0.5 0.08 
Difference within groups (P-value) 0.003 0.43 
 
Intima-media thickness (IMT) (mm) 
Baseline (MF n=19; PL n=20) 0.53 (IQR 0.48 to 0.55) 0.51 (IQR 0.48 to 0.56) 0.75 
At 12 weeks 0.53 (IQR 0.48 to 57) 0.54 (IQR 0.50 to 0.60) 0.67 
Change over 12 weeks -0.02 ± 0.08 0.02 ± 0.05 0.049 
Difference within groups (P-value) 0.62 0.04 
 
Lysis time (sec) 
Baseline (MF n=13; PL n=16) 342.0 (IQR 267.0 to 393.0) 357.0 (IQR 285.0 to 400.5) 0.43 
At 12 weeks 300 (IQR 234 to 324) 360 (IQR 313 to 632) 0.001 
Change over 12 weeks -48.0 (IQR -111.0 to 3.0) 33.0 (IQR -13.5 to 192.0) 0.004 
Difference within groups (P-value) 0.03 0.06 
 
Bone mineral density (BMD) – Total hip (g/cm2) 
Baseline (MF n=16; PL n=21) 1.002 ± 0.150 0.977 ± 0.181 0.66 
At 12 weeks 1.021 ± 0.148 0.974 ± 0.179 0.40 
Change over 12 weeks 0.014 (IQR 0.002 to 0.027) -0.008 (IQR -0.015 to 0.010) 0.005 
Difference within groups (P-value) 0.02 0.44 
 
FGF21 (pg/mL) 
Baseline fasting MF n=19; PL n=19 53.1 (IQR 29.9 to 154.6) 118.9 (IQR 68.8 to 268.6) 0.06 
At 12 weeks 77.0 (IQR 40.0 to 208.0) 34.1 (IQR 18.3 to 147.0) 0.05 
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Change over 12 weeks 7.6 (IQR -30.5 to 169.0) -78.5 (IQR -234.4 to -1.13) 0.03 
Difference within groups (P-value) 0.43 0.03 
 
%change over 12 weeks 5.0 (IQR -23.6 to 252.1) -66.4(IQR -87.3 to -5.0 ) 0.01 
Maximum post-challenge increment from fasting (change over 12 weeks)(MF n=18; PL n=18) 167.2 (IQR -124.4 to 483.7) 109.2 (IQR -291 to 1067) 0.89 
Adiponectin (ng/mL) 
Baseline (MF n=19, PL n= 21) 15.0 (IQR 9.1 to 29.7) 24.1 (IQR 12.8 to 49.5) 0.18 
At 12 weeks 44.9 (IQR 22.7 to 78.1) 15.9 (IQR 7.3 to 39.7) 0.02 
Change over 12 weeks 27.6 ± 36.0 -5.5 ± 32.2 0.004 
Difference within groups (P-value) 0.004 0.14 
 
Global disease activity VAS (mm) - Rheumatology cohort (pre-specified) 
Baseline (MF n=11; PL n=11) 48 (IQR 28 to 74) 68 (IQR 53 to 80) 0.34 
At 12 weeks 32 ± 27 57 ± 23 0.03 
Change over 12 weeks -17 ± 22 -4 ± 32 0.27 
Difference within groups (P-value) 0.02 0.69 
 
 
Table 3. Safety evaluation 
 
 
 Metformin Placebo P-value 
Adverse events (AE) – numbers of episodes reported 
Nausea 19 12 0.13 
Vomiting 8 4 0.22 
Diarrhoea^ 18 8 0.01 
Flatulence 4 2 0.57 
Abdominal discomfort 14 12 0.78 
Constipation 1 3 0.49 
Indigestion 4 3 0.99 
Exacerbation of asthma 8 7 0.99 
Pneumonia 1 7 0.01 
Exacerbation of bronchiectasis 1 0 0.99 
Upper airway viral illness 6 3 0.35 
Gastrointestinal viral illness 2 0 0.33 
Candidosis 0 2 0.33 
Herpes zoster 0 1 0.99 
Ear infection 0 1 0.99 
Diverticulitis 0 1 0.99 
Dental issue (root canal) 1 0 0.99 
Ulcer 2 1 0.99 
Dysglycaemia/osmotic symptoms 5 11 0.08 
Ischemic heart disease/Atrial fibrillation/atypical chest pain# 2 2 0.99 
B12 deficiency 0 2 0.33 
Other (affecting <4% patients: fall, car incident, incidental imaging 
findings, dog bite, schiatica, headache, hematoma etc.) 
14 12 0.78 
Serious adverse events (SAE)* – numbers of episodes reported 
Exacerbation of asthma 0 3 0.10 
Pneumonia 0 1 0.99 
Diverticulitis 0 1 0.99 
Ischemic heart disease 1 0 0.99 
Atypical chest pain 0 1 0.99 
Severe Raynaud’s 0 1 0.99 
Severe osmotic symptoms 0 2 0.33 
All SAEs 1 9 0.001 
 
AE and SAE were defined and reported as per Good Clinical Practice: Here SAE equated to inpatient hospitalizations (≥24h stay). The degree of severity 
was assessed separately to the definition of SAE. The study drugs were not deemed causative of the SAE. The reporting period ended 30 days post 
cessation of treatment. 
 
^10(38%) metformin-treated patients compared to 2 (7%) on placebo reported diarrhoea during the first 4 weeks after treatment initiation (p=0.009) with 
a median symptom resolution of 3 days (IQR 2 to 28) in the metformin cohort and no between-group difference in diarrhoea reports during subsequent 
follow-ups. 
 
The total number of infective episodes was not significantly different between the treatment groups (15 on metformin vs. 21 on placebo, p=0.24), but 
their severity differed. There were 2 moderate or severe infective episodes on metformin compared to 11 on placebo (p=0.001); the incidence of mild 
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infective episodes was similar (13 on metformin compared to 10 on placebo, p=0.56). This suggested 33% (95%CI 12 to 54) absolute risk reduction of 
moderate and severe infective events on metformin (p=0.009) where the number needed to treat was 3 (95%CI 2 to 8). 
 
 During hospital encounters and admissions, glycaemia was monitored and managed as per routine clinical practice, independently of the study. Apart 
from the two subjects developing severe osmotic symptoms, withdrawn from the study, no other patient was deemed to require a glucose-lowering 
pharmacological intervention. 
 
#Ischemic heart disease diagnosed incidentally in an elderly heavy smoker (>40 pack year smoking history) treated with a coronary stenting off the 
investigational medicinal product. 
 
*There were less serious adverse events affecting the respiratory system in the metformin arm (p=0.03). The number of episodes of asthma exacerbations 
was similar; out of these, the proportional rate of severe episodes seemed higher on placebo (p=0.08). Overall, there was a 30% (95%CI 10 to 49) absolute 
risk reduction of serious adverse events on metformin (p=0.01) which suggests about 3 (95% CI 2 to10) patients needing treatment to prevent 1 hospital 
admission. 
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cluded (n=796) 
ot meeting inclusion criteria (n=688) 
eclined to participate (n=108) 
Allocation 
Allocated to Metformin (n=26) 
• Received allocated intervention (n=26) 
• Did not receive allocated intervention (n=0) 
Allocated to Placebo (n=27) 
• Received allocated intervention (n=27) 
• Did not receive allocated intervention 
(n=0) 
Analysed (primary outcome) 
- Intention to treat (n=21) 
Analysed (primary outcome) 
- Intention-to-treat (n=19) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lost to follow-up (n=0) 
Discontinued intervention (n=7)*; 
- significant gastro-intestinal side-effects 
(n=4); 
- unable to adhere to appointment 
schedule (n=3) 
 
Lost to follow-up (n=0) 
Discontinued intervention (n=6)* 
- overt diabetes mellitus (n=2) 
- glucocorticoid dose falling outside of 
inclusion criteria (n=1); 
- unable to adhere to appointment 
schedule (n=3) 
 
Analysis 
 
 
 
 
 
 
 
 
 
 
*Drop-out rates were not different in the metformin and placebo groups. 
 
 
Figure 1. Trial flow diagram 
Assessed for eligibility 
(n=849). The patients were 
selected based on 14 000 
case & lab records reviewed 
on the grounds of 4 hospitals 
of Barts Health NHS Trusts 
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Figure 2. Metformin effects on appetite, pancreas, fat and liver 
Figure 2. legend: Changes over 12 weeks between metformin- and placebo-treated groups in a) truncal subcutaneous fat 
area (p=0.01), b) HbA1c (p=0.007), c) insulin resistance (p=0.04), d) HOMA2%B/HOMA2IR disposition index (p=0.001), 
e) LDL in statin-naïve patients (p=0.03), f) ALT (p=0.03), g) hunger (p=0.04) and h) sugar craving (p=0.01) by 100mm 
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visual analogue scales (VAS). Data are presented as median and interquartile range; data points (a-f) represent individual 
patients. P-values were assessed by T-test/Mann-Whitney (a-f), repeated-measures two-way ANOVA (g, h). 
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Figure 3. Metformin effects on fibrinolysis, inflammation and bone metabolism 
 
Figure 3 legend: Changes over 12 weeks between treatment groups in a) lysis time (p=0.004), b) hsCRP (p=0.04), c) 
dyspnoea 100mm VAS in patients with diseases affecting the respiratory system (p=0.03), d) BMD at the hip (p=0.005), 
e) ßCTX showing individual patient data: changes within-metformin group (p=0.001); changes within-placebo group 
(p=0.82), f) βCTX: between-group difference (p=0.01). Medians with interquartile error bars are presented (a-d, f); data 
points (a, c, d, e, f) represent individual patients. P-values were assessed by T-test/Mann-Whitney (a, c-f) and repeated- 
measures two-way ANOVA (b). 
hsCRP, high sensitivity C-reactive protein; VAS, visual analogue scale; βCTX, β-C-terminal telopeptide; BMD, bone 
mineral density 
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